Greater Effect on Disability Remains the Top Opportunity in Relapsing ... PR Newswire (press release) Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie's daclizumab, and Roche/Genentech's ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva's Copaxone). Surveyed ... |
